Stock DMTK DERMTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases DermTech, Inc.

Equities

DMTK

US24984K1051

Market Closed - Nasdaq
Other stock markets
 21:30:00 10/05/2024 BST 		5-day change 1st Jan Change
0.6247 USD +0.76% Intraday chart for DermTech, Inc. -0.68% -64.30%
04-22 North American Morning Briefing : Stock Futures -2- DJ
04-19 Lake Street Downgrades DermTech to Hold From Buy, Price Target is $0.63 MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
DermTech : Accelaration/Increase of Financial Obligation - Form 8-K
PU
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
BU
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
AQ
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
BU
DermTech : 2023 Q4 Transcript
PU
DermTech Reports Fourth-Quarter 2023 Financial Results
BU
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
BU
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
BU
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test across All Skin Types
AQ
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
BU
DERMTECH SIMPLIFIES THE DERMTECH MELANOMA TEST BY DISCONTINUING THE OPTIONAL TERT ADD-ON ASSAY
AQ
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
BU
DERMTECH ANNOUNCES POSITIVE TOPLINE RESULTS FROM TRUST 2 STUDY EVALUATING THE DERMTECH MELANOMA TEST
AQ
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)
BU
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
BU
DMTK DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – DMTK
BU
DERMTECH ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
DMTK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action - DMTK
PR
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DMTK Stock
  4. News DermTech, Inc.
  5. Press Releases